Back to top

messenger-rna: Archive

Zacks Equity Research

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

MRKPositive Net Change MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

VRTXNegative Net Change ANIPPositive Net Change ADMAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

MRKPositive Net Change MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change